Current Report Filing (8-k)
January 03 2019 - 07:06AM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
January 3, 2019
SYNTHETIC BIOLOGICS, INC.
(Exact name of registrant as specified in
its charter)
Nevada
|
|
001-12584
|
|
13-3808303
|
(State or other jurisdiction of incorporation)
|
|
(Commission File No.)
|
|
(IRS Employer Identification No.)
|
9605 Medical Center Drive, Suite 270
Rockville, MD 20850
(Address of principal executive offices
and zip code)
Registrant’s telephone number, including
area code: (301) 417-4364
N/A
(Former name or former address, if changed
since last report)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
¨
If an emerging growth company, indicate
by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act.
¨
Item 8.01. Other Events
On January 3, 2019, Synthetic Biologics,
Inc. (the “Company”) issued a press release announcing that the first two patients have been enrolled in the SYN-010 Phase 2b investigator-sponsored clinical study. SYN-010 is a proprietary, modified-release reformulation of lovastatin
lactone designed to reduce methane production by certain microorganisms (
M. smithii
) in the gut to treat an underlying cause
of irritable bowel syndrome with constipation (IBS-C). Cedars-Sinai Medical Center and Synthetic Biologics are co-funding the study,
which will further assess the efficacy and safety of SYN-010 in patients diagnosed with IBS-C.
The press release attached as Exhibit 99.1
to this Current Report on Form 8-K, which is incorporated herein by reference, includes “safe harbor” language pursuant
to the Private Securities Litigation Reform Act of 1995, as amended, indicating that certain statements contained in the press
release are “forward-looking” rather than historical.
The Company undertakes no duty or obligation
to update or revise information included in this Current Report on Form 8-K or the press release attached as Exhibit 99.1 hereto.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: January 3, 2019
|
SYNTHETIC BIOLOGICS, INC.
|
|
By:
|
/s/ Steven A. Shallcross
|
|
Name:
|
Steven A. Shallcross
|
|
Title:
|
Chief Executive Officer and
Chief Financial Officer
|
EXHIBIT INDEX
Synthetic Biologics (AMEX:SYN)
Historical Stock Chart
From Feb 2024 to Mar 2024
Synthetic Biologics (AMEX:SYN)
Historical Stock Chart
From Mar 2023 to Mar 2024